Floatz logo

PCK-HGFX7

Critical Limb Ischemia

Helixmith Co., Ltd.gene_therapyPhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Critical Limb Ischemia cohort.

Same molecule, other indications

PCK-HGFX7 is also rated in:

Painful Diabetic NeuropathiesDormant
B
Indicative ·
57 / 100
View asset →
myocardial ischemiaDormant
CCC
Indicative ·
48 / 100
View asset →
amyotrophic lateral sclerosisDormant
CC
Indicative ·
46 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →